Division News

Tom LeBlanc, MD, MA, assistant professor of medicine (Hematological Malignancies and Cellular Therapy) and member of Duke Cancer Institute, has been invited to present at the National Comprehensive Cancer Network's 11th Annual Congress: Hematological Malignancies on Oct. 1.

Three Department of Medicine faculty will serve as featured voices on Twitter for the American Society of Clinical Oncology's annual, national meeting in Chicago June 3-7. 

Arif Kamal, MD, MBA, assistant professor of medicine (Medical Oncology), and Thomas LeBlanc, MD, assistant professor of medicine (Hematological Malignancies and Cellular Therapy), published an online article in JAMA Viewpoint on May 31.

Scientists at the Duke Cancer Institute have identified a molecular key that breast cancer cells use to invade bone marrow in mice, where they may be protected from chemotherapy or hormonal therapies that could otherwise eradicate them. 

Four Department of Medicine faculty were recently awarded Enhanced Academics in a Basic Laboratory Environment (ENABLE) program research grants from the PDC. 

Each year, in communities across the country, passionate candidates engage in an exciting competition to earn The Leukemia & Lymphoma Society's "Man & Woman of the Year" titles by raising funds for LLS blood cancer research. The candidates compete in honor of children who are local blood cancer survivors, the Boy & Girl of the Year. 

Nelson Chao, MD, MBA, professor of medicine and chief of the Division of Hematological Malignancies and Cellular Therapy, was featured recently in a story by WRAL about a study he is conducting comparing in-home stem cell treatments to those done in the hospital setting.

Watch a video on WRAL's website.

Thomas LeBlanc, MD, assistant professor of medicine (Hematological Malignancies and Cellular Therapy), is one of 10 recipients of a two-year, $180,000 grant from the Cambia Health Foundation through its annual Sojourns Scholar Leadership Program.

Stefanie Sarantopoulos, MD, PhD, associate professor of medicine (Hematological Malignancies and Cellular Therapy) has received notice of her first R01 award from NIH to to determine mechanisms that drive or suppress pathological B cells after hematopoietic cell transplantation, so that targeted and preventative therapies can be effectively devised.

Internationally recognized for its novel approaches to treating leukemia, lymphoma and multiple myeloma, the Duke Cancer Institutes’s Adult Bone Marrow Transplant (ABMT) Program celebrates its 30th anniversary in June 2015. The program, which performs about 300 transplants annually, is expected to have administered its 5,000th transplant by the end of June.